# ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)

> **NCT02955615** · PHASE2 · COMPLETED · sponsor: **Iltoo Pharma** · enrollment: 100 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** ILT-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02955615
- **Lead sponsor:** Iltoo Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-18
- **Primary completion:** 2018-08-27
- **Final completion:** 2019-02-11
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2019-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02955615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02955615, "ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02955615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*